DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
CERC-301 is an investigational drug.
There have been 7 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Indiana University.
There are ten US patents protecting this investigational drug and one hundred and forty international patents.
Recent Clinical Trials for CERC-301
|Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury||Aevi Genomic Medicine, LLC, a Cerecor company||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Cerecor Inc||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||National Institute on Drug Abuse (NIDA)||Phase 2|
Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CERC-301||Get Started Free||Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists||Rugen Holdings (Cayman) Limited (Grand Cayman, KY)||Get Started Free|
|CERC-301||Get Started Free||Class of mu-opioid receptor agonists||THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY)||Get Started Free|
|CERC-301||Get Started Free||Compounds, compositions and methods||CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)||Get Started Free|
|CERC-301||Get Started Free||3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists||RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CERC-301||Argentina||AR100733||2034-06-04||Get Started Free|
|CERC-301||Australia||AU2015271719||2034-06-04||Get Started Free|
|CERC-301||Canada||CA2950285||2034-06-04||Get Started Free|
|CERC-301||China||CN106795163||2034-06-04||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|